All In Biotech

Drug Trial Radar · NCT06865651

Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria

A 12-week Randomized, Participant and Investigator-blinded, Placebo-controlled, Exploratory Study in Adult Participants With Chronic Urticaria to Assess the Efficacy and Safety and Explore the Mechanism of Action of Remibrutinib (LOU064)

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

44

Planned (sponsor's estimate)

Start

May 22, 2025

Primary completion

Aug 23, 2027

Study completion Sep 28, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to explore the effect and Mechanism of Action (MoA) of remibrutinib (LOU064) vs. placebo on clinical outcomes in participants with Chronic Urticaria (CU), including both Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CINDU).

Conditions

  • Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)

Interventions

  • RemibrutinibDrug

    tablets

  • PlaceboDrug

    tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change from baseline in the weekly most bothersome symptom Numeric Rating Scale (NRS) score on the Urticaria Symptom Daily Diary (USDD)Time frame: Baseline, Week 6
  2. Absolute change from baseline in Urticaria Control Test 7 (UCT7) weekly scoresTime frame: Baseline, Week 6

Locations

17 sites in 5 countries. Site status is shown where the registry gives one.

  • Ziaderm Research LLC

    North Miami Beach, Florida · Recruiting

  • Endeavor Health

    Glenview, Illinois · Recruiting

  • Novartis Investigative Site

    Grenoble, France · Recruiting

  • Novartis Investigative Site

    Montpellier, France · Recruiting

  • Novartis Investigative Site

    Paris, France · Recruiting

  • Novartis Investigative Site

    Pierre-Bénite, France · Recruiting

  • Novartis Investigative Site

    Berlin, Germany · Recruiting

  • Novartis Investigative Site

    Mainz, Germany · Withdrawn

  • Novartis Investigative Site

    Tübingen, Germany · Recruiting

  • Novartis Investigative Site

    Dresden, Saxony, Germany · Recruiting

  • Novartis Investigative Site

    Poznan, Poland · Recruiting

  • Novartis Investigative Site

    Rzeszów, Poland · Withdrawn

  • Novartis Investigative Site

    Warsaw, Poland · Withdrawn

  • Novartis Investigative Site

    Alicante, Spain · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain · Recruiting

  • Novartis Investigative Site

    Pamplona, Navarre, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.